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Objectives The aim of this study was to characterize the relationship between pericardial fat and atrial fibrillation (AF).
Background Obesity is an important risk factor for AF. Pericardial fat has been hypothesized to exert local pathogenic effects
on nearby cardiac structures above and beyond that of systemic adiposity.
Methods One hundred ten patients undergoing first-time AF ablation and 20 reference patients without AF underwent car-
diac magnetic resonance imaging for the quantification of periatrial, periventricular, and total pericardial fat vol-
umes using a previously validated technique. Together with body mass index and body surface area, these were
examined in relation to the presence of AF, the severity of AF, left atrial volume, and long-term AF recurrence
after ablation.
Results Pericardial fat volumes were significantly associated with the presence of AF, AF chronicity, and AF symptom
burden (all p values 0.05). Pericardial fat depots were also predictive of long-term AF recurrence after ablation
(p  0.035). Finally, pericardial fat depots were also associated with left atrial volume (total pericardial fat: r 
0.46, p  0.001). Importantly, these associations persisted after multivariate adjustment and additional adjust-
ment for body weight. In contrast, however, systemic measures of adiposity, such as body mass index and body
surface area, were not associated with these outcomes in multivariate-adjusted models.
Conclusions Pericardial fat is associated with the presence of AF, the severity of AF, left atrial volumes, and poorer outcomes
after AF ablation. These associations are both independent of and stronger than more systemic measures of
adiposity. These findings are consistent with the hypothesis of a local pathogenic effect of pericardial fat on the
arrhythmogenic substrate supporting AF. (J Am Coll Cardiol 2011;57:1745–51) © 2011 by the American Col-
lege of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.11.045f
t
bAtrial fibrillation (AF) is the most common sustained
arrhythmia, and its prevalence has been projected to con-
tinue to increase significantly in the coming decades (1–3).
ecent studies have highlighted obesity and body size as risk
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Pericardial Fat and Atrial Fibrillation April 26, 2011:1745–51adipose tissue depots have only
recently been shown to be asso-
ciated with AF (9,10). In addi-
tion, no study has quantified
periatrial and periventricular fat
volumes in relation to AF.
The aim of the present study
was thus to characterize the rela-
tionship between specific pericar-
dial fat depots, as measured by
cardiac magnetic resonance imaging (MRI), and AF. We
sought to determine whether pericardial fat depots were
associated with the presence and severity of AF, as assessed by
AF chronicity and symptom burden. In addition, we also
explored the association of these depots with left atrial (LA)
volume and ablation outcome. Because of its contiguity to
cardiac structures, we hypothesized that specific pericardial fat
depots would be associated with the presence and severity of AF,
larger LA volumes, and poorer outcomes after AF ablation.
Methods
Study population. Consecutive patients (n  110) under-
going first-time ablation with no contraindications to MRI
were recruited into 3 groups on the basis of AF chronicity,
in accordance with the Heart Rhythm Society expert con-
sensus statement (11). Paroxysmal AF was defined as
ecurrent AF that terminates spontaneously within 7 days.
ersistent AF was defined as AF that is sustained beyond 7
ays or that lasts 7 days but necessitates pharmacological
r electrical cardioversion. Permanent AF was defined as
F of1 year in duration in which cardioversion has either
ailed or not been attempted. AF symptom burden was
Abbreviations
and Acronyms
AF  atrial fibrillation
BMI  body mass index
BSA  body surface area
LA  left atrial
MRI  magnetic resonance
imaging
Study Sample CharacteristicsTable 1 Study Sample Characteristics
Variable AF (n  102
Age (yrs) 58 9
Men 76% (72)
BMI (kg/m2) 28.0 3.5
BSA (m2) 2.04 0.22
Periatrial fat (cm3) 118.5 (70.8–17
Periventricular fat (cm3) 154.7 (114.4–23
Total pericardial fat (cm3) 299.9 (192.2–40
Paroxysmal AF 37% (38)
Persistent AF 33% (34)
Permanent AF 29% (30)
AF episode frequency score 8.5 1.9
AF episode duration score 8.5 2.1
LA volume (ml) 123 36
Valvulopathy 6.9% (7)
Hypertension 56.9% (58)
Diabetes 5.9% (6)
Ischemic heart disease 17.6% (18)
Left ventricular dysfunction 14.7% (15)
Obstructive sleep apnea 17.6% (18)Data are expressed as mean  SD, as % (n), or as median (interquartile rang
AF  atrial fibrillation; BMI  body mass index; BSA  body surface area;valuated in these patients using the University of Toronto
trial Fibrillation Severity Scale (12). A reference group of
0 volunteers without AF was also studied. The 2 groups
ere well matched with regard to cardiovascular risk factors
nd systemic adiposity (Table 1).
All patients provided written informed consent for the study
rotocol, which was approved by the Clinical Research and
thics Committee of the Royal Adelaide Hospital.
RI protocol and analysis. Patients underwent cardiac
RI at 1.5 T (Siemens Avanto, Siemens Medical Solu-
ions, Erlangen, Germany) in the week before ablation.
equential steady-state free-precession short-axis cine se-
uences were acquired with 6-mm slice thickness and no
nterslice gaps through the atria and 6-mm slice thickness
ith 4-mm gaps through the ventricles. Slices were taken
rom the most cranial aspect of the left atrium and sequentially
o the cardiac apex at end-expiration. The atria were addition-
lly imaged in the horizontal long-axis plane with 6-mm
lice-thickness and no interslice gaps. Typical imaging param-
ters were as follows: echo time 1.2 ms, repetition time 63.7
s, flip angle 80°, matrix size 192 156, and field of view 360
o 440 mm. Of 110 subjects, 8 scans were uninterpretable
ecause of motion artifacts, leaving 102 in the study sample.
Pericardial fat volumes were measured offline by 2 blinded
bservers using proprietary software (Argus, Siemens Medical
olutions). Fat volumes were quantified using a previously
alidated technique found to be highly accurate and repro-
ucible by our group in an ex vivo ovine model (13).
ericardial fat was defined as regions of high signal intensity
etween the myoepicardium and the parietal pericardium.
eriatrial and periventricular fat was defined as any pericardial
at subtending the atria and ventricles, respectively (Fig. 1).
Reference (n  20) p Value
54 6 0.15
11% (55) 0.20
27.2 3.4 0.46
1.93 0.20 0.08
69.7 (47.7–88.0) 0.001
101.2 (84.9–111.2) 0.001
168.8 (130.4–189.0) 0.001
— —
— —
— —
— —
— —
90 26 0.006
0.0% (0) 0.60
55.0% (11) 0.99
10.0% (2) 0.61
10.0% (2) 0.52
5.0% (1) 0.47
10.0% (2) 0.52)
3.8)
3.8)
7.2)e).
LA  left atrial.
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April 26, 2011:1745–51 Pericardial Fat and Atrial FibrillationAreas of fat were traced on consecutive end-diastolic short-
axis images and multiplied by the slice thickness to derive
volume (13). Intraobserver and interobserver reproducibility
with this technique was excellent (coefficients of variation
3.5% and 4.9%, respectively). LA volumes were deter-
mined by manually tracing endocardial borders in the
horizontal long-axis views in ventricular end-systole and
calculated using a modified Simpson’s rule (14).
isk factor definitions. Body mass index (BMI) was
alculated as weight in kilograms divided by the square of
Figure 1 Volumetric MRI Assessment of Periatrial
and Periventricular Fat
Example magnetic resonance imaging (MRI) slices depicting volumetric assess-
ment of periatrial (A) and periventricular (B) fat depots. Areas of pericardial fat
are shaded in blue.eight in meters, and body surface area (BSA) was calcu- rlated using the Mostellar formula (15). The following risk
factors were ascertained as categorical variables: sex, hyper-
tension, diabetes mellitus, ischemic heart disease, left ven-
tricular dysfunction, valvulopathy, and obstructive sleep
apnea. LA volume was determined as previously discussed.
Electrophysiology study and ablation. The electrophysi-
ological procedure was performed in the post-absorptive
state with conscious sedation using midazolam and fentanyl.
The ablation technique has been previously described (16).
In brief, a conventional transseptal puncture was used to
advance both a circular mapping catheter (Lasso, Biosense
Webster, Diamond Bar, California) and a 3.5-mm-tip
externally irrigated ablation catheter (ThermoCool, Bio-
sense Webster). After transseptal puncture, unfractionated
heparin was administered (100 IU/kg), with repeated bo-
luses to maintain an activated clotting time of 300 to 350 s.
Electroanatomic mapping (CARTO, Biosense Webster; or
NavX, St. Jude Medical, St. Paul, Minnesota) was used for
nonfluoroscopic navigation. The ablation strategy included
wide-encircling ablation of the pulmonary veins with an
endpoint of pulmonary vein isolation and further substrate
modification using linear ablation or electrogram-based
ablation in those with AF paroxysms 48 h, large atria
(largest diameter 57 mm), or evidence of structural heart
disease. Radiofrequency power of 30 W was used, with
irrigation rates of 30 to 60 ml/min.
Follow-up. Patients were followed at 3, 6, 9, 12, 18, and 24
months, and then yearly, until AF recurrence. At each
review, patients underwent ambulatory monitoring for a
7-day period. All patients received either flecainide or
sotalol for 6 weeks after the procedure. Antiarrhythmic
drugs were ceased at the discretion of the treating physician
at the 6-week follow-up visit. Warfarin was continued in all
patients for at least 3 months. In patients with CHADS2
scores 2, warfarin was ceased in the absence of any
rrhythmia; otherwise, it was continued for a minimum of
2 months. Procedural success was determined as the
bsence of any atrial arrhythmia 30 s without the use of
ntiarrhythmic drugs after a blanking period of 3 months.
tatistical analysis. To study the relationship between
ericardial fat and AF presence, we used binary logistic
egression models. Each adiposity measure was then studied
eparately, adjusting for the 2 strongest univariate risk
actors (LA volume and obstructive sleep apnea) to avoid
verfitting and then additionally for weight.
To determine the relationship between pericardial fat
epots and AF chronicity, we compared pericardial fat
epots according to AF chronicity using the Kruskal-Wallis
est and post hoc Wilcoxon rank sum tests as appropriate.
e then dichotomized the study sample into 2 groups:
aroxysmal and nonparoxysmal AF (persistent or permanent
F). Each adiposity measure was then studied separately,
djusting for the 4 strongest univariate risk factors (LA volume,
eft ventricular dysfunction, sex, and valvulopathy) to avoid
verfitting and then additionally for weight. To determine the
elationship between pericardial fat and AF symptom burden
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Pericardial Fat and Atrial Fibrillation April 26, 2011:1745–51scores, multivariate linear regression models were used, adjust-
ing for all the aforementioned risk factors and AF chronicity
and then additionally for weight.
To determine the relationship between pericardial fat and
AF recurrence, patients were first divided into tertiles
according to total pericardial fat, and Kaplan-Meier meth-
ods were used. Second, a time-to-event Cox proportional-
hazards regression method was used to study the individual
relationships of specific adiposity measures as continuous
variables to long-term AF recurrence. Multivariate Cox
proportional-hazards regression models were used adjusting for
all the aforementioned risk factors and AF chronicity and then
additionally for weight. The proportional-hazards assumption
was confirmed by means of the Schoenfeld residuals test; no
relevant violations of the assumption were found.
To determine the relationship between pericardial fat and
LA volume, Pearson’s correlations between adiposity mea-
sures and LA volume were calculated. Multivariate linear
regression models were then constructed to determine
which specific adiposity measures were associated with LA
volumes, adjusting for all the aforementioned risk factors
and then additionally for weight.
Figure 2 Pericardial Fat According to the Presence
and Severity of AF
Box plots are shown depicting specific pericardial fat depot volumes according
to the presence and chronicity of atrial fibrillation (AF). There is a clear dose-
response relationship between pericardial fat volumes and both the presence
of and chronicity of AF.
Multivariate-Adjusted Odds Ratios (Confidence Intervals) of AdiposTable 2 Multivariate-Adjusted Odds Ratios (Confidence Interva
Variable Univariate p Value Multivariate Ad
BMI 1.26 (0.74–2.15) 0.391 1.16 (0.61–2
BSA 1.61 (0.94–2.73) 0.081 1.25 (0.65–2
Periatrial fat 4.61 (1.72–12.39) 0.002 5.35 (1.30–2
Periventricular fat 13.63 (3.04–61.15) 0.001 10.94 (1.69–7
Total pericardial fat 10.47 (2.87–38.21) 0.001 11.25 (2.07–6Abbreviations as in Table 1.Continuous variables are reported as mean  SD or as
edian and interquartile range as appropriate. Study sample
haracteristics according to group were compared using the
npaired Student t tests, Wilcoxon rank sum tests, or Fisher
xact tests as appropriate. All adiposity measures were stan-
ardized to a mean of 0 and an SD of 1 to facilitate comparison
etween different fat depots. Statistical tests were performed
sing SPSS version 16 (SPSS, Inc., Chicago, Illinois), and
-tailed p values 0.05 were considered significant.
esults
atient characteristics. Patient characteristics are summa-
ized in Table 1. The 2 groups were well matched for age,
ex, and risk factors. However, patients with AF had larger
eft atria (p  0.006).
ericardial fat and AF presence. Patients with AF had
reater pericardial fat volumes than reference patients (Fig. 2).
y logistic regression modeling, pericardial fat depots were
ndividually predictive of the presence of AF (Table 2),
hereas systemic adiposity measures were not. Additional
djustment for risk factors and weight did not change these
ssociations.
ericardial fat and AF severity. Worsening baseline AF
hronicity was associated with greater adiposity measures
Fig. 2). All adiposity measures were individually predictive
f nonparoxysmal AF (Table 3). However, only pericardial
at volumes were associated with nonparoxysmal AF in
ultivariate-adjusted models, and additional adjustment for
eight did not change these associations.
Similarly, although all adiposity measures were individu-
lly associated with AF burden score, only pericardial fat
olumes were still associated after multivariate adjustment
Table 4). Additional adjustment for weight also did not
hange these associations.
ericardial fat and AF recurrence. There was no loss to
ollow-up after 16.7  11.1 months. Of 102 patients, 43
42.6%) remained free of recurrence while off antiarrhyth-
ic drugs after a single ablation procedure. Of those with
ecurrence (n  59), 32 were recommenced on antiarrhyth-
ic drugs, and 14 (43.8%) responded favorably to previously
neffective antiarrhythmic drugs after ablation and main-
ained normal sinus rhythm. Of the 59 patients with
ecurrence, 37 went on to have second procedures, and 5
ent on to have third procedures. After 1.4  0.6 proce-
ures and 21.0  12.0 months after the last procedure, 90
easures and the Presence of AFAdiposity Measures and the Presence of AF
p Value With Additional Adjustment for Body Weight p Value
0.645 — —
0.509 — —
0.020 5.33 (1.25–22.66) 0.023
0.012 11.97 (1.69–84.88) 0.013
0.005 13.28 (2.23–79.98) 0.005ity Mls) of
justed
.22)
.41)
.19)
0.73)
1.24)
a
a
(
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rhythmic drugs.
By Kaplan-Meier analysis, patients with more extensive
total pericardial fat had recurrence at earlier time points
after the index ablation procedure (p  0.035 by log-rank
test) (Fig. 3).
Pericardial fat volumes were predictive of AF recurrence
by Cox regression modeling, whereas BMI and BSA were
not (Table 5). After multivariate adjustment, periventricular
fat (p  0.024) remained predictive of AF recurrence. This
association remained significant after additional adjustment
for weight (p  0.025).
Pericardial fat and LA volume. Periatrial (r  0.43),
periventricular (r 0.48), and total pericardial (r 0.49) fat
volumes were correlated with LA volume (all p values 
0.001). In contrast, neither BMI nor BSA was significantly
correlated with LA volume (p  0.22 and p  0.38,
respectively).
In multivariate-adjusted models, all pericardial fat depots
were associated with LA volume. Per 1-SD increase in
periatrial fat, periventricular fat, and total pericardial fat, LA
volume was 12.10 ml (p  0.004), 12.34 ml (p  0.003),
nd 14.04 ml (p  0.001) larger, respectively. These
ssociations persisted after additional adjustment for weight
p  0.041 for periatrial, p  0.024 for periventricular, and
p  0.022 for total pericardial fat).
Discussion
Major findings. In consecutive patients with AF present-
ing for first-time radiofrequency ablation and a group of
reference patients, we undertook detailed MRI examination
to present new information regarding the interrelationships
between localized pericardial fat depots and AF.
First, we showed there to be an association between
pericardial fat and the presence of AF. Second, we demon-
strated there to be a strong dose-response association
Multivariate-Adjusted Odds Ratios (Confidence Intervals) of AdiposTable 3 Multivariate-Adjusted Odds Ratios (Confidence Interva
Variable Univariate p Value Multivariate Adju
BMI 1.76 (1.08–2.87) 0.024 1.72 (0.89–3.3
BSA 2.05 (1.27–3.30) 0.003 1.57 (0.74–3.3
Periatrial fat 4.64 (2.20–9.76) 0.001 4.87 (1.87–12.
Periventricular fat 2.67 (1.46–4.89) 0.001 2.10 (1.08–4.0
Total pericardial fat 4.33 (2.08–9.02) 0.005 3.56 (1.41–9.0
Abbreviations as in Table 1.
Multivariate-Adjusted Regressions (Confidence Intervals) BetweenTable 4 Multivariate-Adjusted Regressions (Confidence Interva
Variable Univariate p Value Multivariate Ad
BMI 1.10 (0.33 to 1.88) 0.005 0.87 (0.49 to
BSA 1.18 (0.42 to 1.94) 0.003 1.00 (0.32 to
Periatrial fat 1.57 (0.88 to 2.27) 0.001 1.71 (0.79 to 2
Periventricular fat 1.46 (0.74 to 2.19) 0.001 1.21 (0.23 to 2
Total pericardial fat 1.69 (0.99 to 2.39) 0.001 1.71 (0.73 to 2Abbreviations as in Table 1.between pericardial fat and AF severity, as assessed by AF
chronicity and symptom burden. Third, our data demon-
strate that pericardial fat was independently predictive of
AF recurrence after ablation. Finally, we found independent
associations between pericardial fat depots and LA volume.
These associations were not seen with more systemic
measures of adiposity. Our findings are consistent with the
hypothesis of a local pathogenic effect of pericardial fat
promoting an arrhythmogenic substrate.
Pericardial fat and AF. Significant associations between
BMI and the development of AF have been reported
(4–7,17). Prior studies have shown that the association with
BMI is stronger for sustained AF than it is for less severe
forms and that obesity causes progression to more severe AF
(6,18). Short-term increases in BMI have also been associ-
ated with increased AF risk (4). A recent report has
suggested that total pericardial fat volume measured on
computed tomography is associated with prevalent AF (9).
Another recent study reported an association between epi-
cardial thickness over the left atrium on computed tomog-
raphy and AF chronicity (10). The present investigation
extends the results of these studies to a cohort of patients
who had specific pericardial fat volumes measured with a
previously validated MRI technique (13). After multivariate
adjustment, only pericardial fat, and not systemic adiposity
measures, remained independently predictive of both the
presence and severity of AF. Although studies with larger
samples have previously reported associations between sys-
temic adiposity and AF, the finding that pericardial fat but
not systemic adiposity was significantly associated with AF
in our study suggests that pericardial fat depots may be more
influential than BMI or BSA. Furthermore, we found that
pericardial fat was predictive of ablation outcomes, provid-
ing evidence of the deleterious role that pericardial fat may
also have on substrate remodeling after ablation.
easures and AF ChronicityAdiposity Measures and AF Chronicity
p Value With Additional Adjustment for Body Weight p Value
0.108 — —
0.243 — —
0.001 4.84 (1.75–13.4) 0.002
0.030 1.96 (1.01–3.82) 0.047
0.007 3.28 (1.25–8.59) 0.015
osity Measures and AF Burdenetween Adiposity Measures and AF Burden
p Value With Additional Adjustment for Body Weight p Value
0.205 — —
0.133 — —
0.001 1.59 (0.59 to 2.60) 0.003
0.017 1.11 (0.11 to 2.11) 0.031
0.001 1.57 (0.54 to 2.60) 0.003ity Mls) of
sted
2)
3)
69)
9)
0)Adipls) B
justed
2.24)
2.33)
.64)
.19)
.68)
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Pericardial Fat and Atrial Fibrillation April 26, 2011:1745–51Pericardial fat and cardiac structure. Pericardial fat has
been previously shown to be associated with LA dimensions
(19–22). However, periatrial and periventricular fat has not
been previously studied in relation to LA volume, a superior
predictor of outcome to LA dimension (23). We found that
specific pericardial fat depots were associated with MRI-
assessed LA volumes. In contrast, we observed no such
association between systemic adiposity and LA volume.
This may reflect our small sample size compared with
previous epidemiological studies, our use of LA volume, or
the AF population studied. Nevertheless, our data suggest
that pericardial fat may have a pathogenic effect on the
anatomically contiguous atria, above and beyond systemic
effects of generalized adiposity.
Potential mechanisms. The association between pericar-
ial fat and AF was not weakened by risk factor adjustment,
uggesting that they play a lesser role in mediating the
elationship. Previous studies have reported that the associ-
tion between BMI and AF was attenuated when LA
imension was accounted for, suggesting that LA enlarge-
ent accounts for this association (17). We found that
ericardial fat, but not systemic adiposity, was associated
ith LA volume. Furthermore, adjustment for LA volume
Figure 3 Pericardial Fat and Ablation Outcome
Kaplan-Meier curves showing the proportion of patients who maintained sinus
rhythm after a single ablation procedure according to total pericardial fat
tertiles.
Multivariate-Adjusted Hazard Ratios (Confidence Intervals) of AdipoTable 5 Multivariate-Adjusted Hazard Ratios (Confidence Interv
Univariate p Value Multivariate Adju
BMI 1.03 (0.79–1.34) 0.842 0.72 (0.35–1.4
BSA 1.27 (0.96–1.67) 0.096 1.07 (0.47–2.4
Periatrial fat 1.34 (1.05–1.71) 0.020 0.69 (0.30–1.5
Periventricular fat 1.55 (1.23–1.96) 0.001 3.83 (1.19–12.
Total pericardial fat 1.51 (1.19–1.90) 0.001 1.42 (0.56–3.5Abbreviations as in Table 1.id not attenuate the association between pericardial fat, the
resence and severity of AF, and ablation outcomes. Thus,
lthough previous reports have explained the association
etween obesity and AF as due to LA enlargement, our
ndings suggest that the association between pericardial fat
easures and AF are independent of LA size.
Circulating markers of inflammation, microvasculopathy,
nd hemodynamic strain have been linked to AF and obesity
24,25). At a local level, pericardial fat has been associated with
ncreased expression of numerous inflammatory markers (26).
ntracardiac inflammatory markers have also been observed to
e greater than peripheral inflammatory markers, and greatest
n the left atrium, which plays a critical role in AF genesis (27).
ytokines have also been shown to activate fibroblasts, with
he extracellular matrix deposition and fibrosis causing electro-
natomical remodeling (28). Therefore, the present finding
hat only pericardial fat measures are associated with AF
upports the notion that pericardial fat, the local fat depot, may
xert deleterious effects on the anatomically contiguous atria
nd promote arrhythmogenesis.
mplications. We demonstrate that pericardial fat volumes
re associated with the presence and severity of AF, inde-
endent of other risk factors and systemic adiposity. With
he increasing use of cardiac MRI, pericardial fat measure-
ent may yield additional information on the risk for
eveloping AF, the risk for AF progressing, and the risk for
ecurrence after ablation and thereby constitute a novel risk
arker. With the emerging significance of obesity in car-
iovascular disease, further investigation is required into the
nderlying pathophysiological mechanisms.
tudy limitations. The cross-sectional study design limits
nferences of causality. The predominantly white Australian
atient sample also limits the generalizability of our findings
o nonwhite subjects. We also did not measure waist
ircumference or waist-to-hip ratio; these measures may
ave added incremental information on the effects of local
ersus systemic adiposity. Finally, because of small subgroup
izes, the number of variables adjusted for in the binary
ogistic regression models was limited to avoid overfitting
odels.
onclusions
ericardial fat is associated with the presence and severity of
F, LA volumes, and poorer outcomes after AF ablation.
hese associations are both independent of and stronger
Measures and AF Recurrenceof Adiposity Measures and AF Recurrence
p Value With Additional Adjustment for Body Weight p Value
0.364 — —
0.874 — —
0.366 0.60 (0.25–1.46) 0.259
0.024 3.95 (1.19–3.34) 0.025
0.465 1.39 (0.52–3.67) 0.509sityals)
sted
7)
2)
5)
29)
9)
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April 26, 2011:1745–51 Pericardial Fat and Atrial Fibrillationthan more systemic measures of adiposity. Our findings are
consistent with the hypothesis of a local pathogenic effect of
pericardial fat on the arrhythmogenic substrate supporting AF.
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